SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The New Economy and its Winners
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Fowler who wrote (4373)12/21/2000 12:03:45 AM
From: Bill Harmond  Read Replies (1) of 57684
 
Yeah, Yeah, Mark. :) You could be right, but I consider biotechs a defensive group, and the latest findings on Riruxan are even more compelling, monthly sequential sales are increasing (except for this pre-holiday period, naturally) treatments are being extended in length. Sales could hit $600 million next year. This is life and death.

Rituxan is a home-run medicine. Whatever you do you're shorting into super fundamentals, probably the industry's best.

...and to think I sold mine at 140 or something. See, buy and hold.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News